SCHEMBL5134791

SCHEMBL5134791

CCC(=O)Cc1ccc(Oc2ncnc(N3CCC(c4nc(C)no4)CC3)c2[N+](=O)[O-])cc1

nearest known ligand 0.56

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 20/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL388967 0.88 GPR119 (0.70) GPR119
SCHEMBL1673972 0.85 GPR119 (0.52) GPR119
SCHEMBL28759189 0.84 GPR119 (0.54) GPR119
SCHEMBL2730356 0.77 GPR119 (0.55) GPR119
SCHEMBL12733640 0.76 GPR119 (0.53) GPR119
SCHEMBL388697 0.76 GPR119 (0.78) GPR119
SCHEMBL5260174 0.73 GPR119 (0.67) GPR119
SCHEMBL1673791 0.73 GPR119 (0.67) GPR119
SCHEMBL1673669 0.73 GPR119 (0.84) GPR119
SCHEMBL12733498 0.73 GPR119 (0.86) GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2004157-A2 USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO Arena Pharmaceuticals, Inc. (US) 2008-12-24 EP disclosed
WO-2007120702-A2 USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO ARENA PHARMACEUTICALS, INC. (US) 2007-10-25 WO disclosed